CAPLYTA (Lumateperone) Shows Significant And Rapid Improvement In Bipolar Mania In Pivotal Phase 3 Study
JNJ•Phase 3 bipolar mania study results
Johnson & Johnson said CAPLYTA® (lumateperone) showed significant and rapid improvement in bipolar mania in a pivotal Phase 3 study.
- CAPLYTA demonstrated statistically significant rapid reduction in manic symptoms at week 3.
- J&J said CAPLYTA was well-tolerated; dry mouth and nausea were the most common adverse events.
